NK
Insider
Najat Khan
Chief R&D Commercial OfficerNajat Khan (Chief R&D Commercial Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Recursion Pharmaceuticals, Inc. (RXRX). The largest single filing was $549K of RXRX (124,403 sh × $4.41, as filed), executed Dec 22 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells · 1 late
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$549K
shares × price, as filed
Last traded
Dec 22 2025
Filed Dec 29 2025
Median ADV $67.5M across their filed names
Open performance→Volume by month
Buys $0
Sells $751K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
RXRXRecent filings
RXRXSALE
Recursion Pharmaceuticals, Inc.
View filing →
$549K124,403 sh × $4.41
Exec Dec 22 2025
Filed Dec 29 2025 · 5:30 PM ET † RXRXSALE Recursion Pharmaceuticals, Inc. View filing → $202K
36,599 sh × $5.52
Exec Aug 18 2025
Filed Aug 19 2025 · 5:30 PM ET